These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 29865854)
1. BDNF and Tau as biomarkers of severity in multiple sclerosis. Islas-Hernandez A; Aguilar-Talamantes HS; Bertado-Cortes B; Mejia-delCastillo GJ; Carrera-Pineda R; Cuevas-Garcia CF; Garcia-delaTorre P Biomark Med; 2018 Jul; 12(7):717-726. PubMed ID: 29865854 [TBL] [Abstract][Full Text] [Related]
2. Fitness Shifts the Balance of BDNF and IL-6 from Inflammation to Repair among People with Progressive Multiple Sclerosis. Devasahayam AJ; Kelly LP; Williams JB; Moore CS; Ploughman M Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33810574 [TBL] [Abstract][Full Text] [Related]
3. Serum and saliva total tau protein as a marker for relapsing-remitting multiple sclerosis. Mirzaii-Dizgah MH; Mirzaii-Dizgah MR; Mirzaii-Dizgah I Med Hypotheses; 2020 Feb; 135():109476. PubMed ID: 31733529 [TBL] [Abstract][Full Text] [Related]
4. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
5. Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. Michalicova A; Majerova P; Kovac A Front Mol Neurosci; 2020; 13():570045. PubMed ID: 33100967 [TBL] [Abstract][Full Text] [Related]
6. Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. Naegelin Y; Saeuberli K; Schaedelin S; Dingsdale H; Magon S; Baranzini S; Amann M; Parmar K; Tsagkas C; Calabrese P; Penner IK; Kappos L; Barde YA Ann Clin Transl Neurol; 2020 Nov; 7(11):2251-2261. PubMed ID: 33031634 [TBL] [Abstract][Full Text] [Related]
7. Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker? Abdelhak A; Hottenrott T; Morenas-Rodríguez E; Suárez-Calvet M; Zettl UK; Haass C; Meuth SG; Rauer S; Otto M; Tumani H; Huss A Front Neurol; 2019; 10():280. PubMed ID: 30972011 [No Abstract] [Full Text] [Related]
9. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913 [TBL] [Abstract][Full Text] [Related]
10. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845 [No Abstract] [Full Text] [Related]
11. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Ayrignac X; Le Bars E; Duflos C; Hirtz C; Maleska Maceski A; Carra-Dallière C; Charif M; Pinna F; Prin P; Menjot de Champfleur N; Deverdun J; Kober T; Marechal B; Fartaria MJ; Corredor Jerez R; Labauge P; Lehmann S Sci Rep; 2020 Jul; 10(1):10923. PubMed ID: 32616916 [TBL] [Abstract][Full Text] [Related]
12. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. Harris S; Comi G; Cree BAC; Arnold DL; Steinman L; Sheffield JK; Southworth H; Kappos L; Cohen JA; Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643 [TBL] [Abstract][Full Text] [Related]
13. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Momtazmanesh S; Shobeiri P; Saghazadeh A; Teunissen CE; Burman J; Szalardy L; Klivenyi P; Bartos A; Fernandes A; Rezaei N Rev Neurosci; 2021 Aug; 32(6):573-595. PubMed ID: 33594840 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. Huss A; Senel M; Abdelhak A; Mayer B; Kassubek J; Ludolph AC; Otto M; Tumani H Biomedicines; 2020 Aug; 8(9):. PubMed ID: 32872144 [TBL] [Abstract][Full Text] [Related]
15. A Score Based on NfL and Glial Markers May Differentiate Between Relapsing-Remitting and Progressive MS Course. Huss A; Otto M; Senel M; Ludolph AC; Abdelhak A; Tumani H Front Neurol; 2020; 11():608. PubMed ID: 32765393 [No Abstract] [Full Text] [Related]
16. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436 [TBL] [Abstract][Full Text] [Related]